This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects

This study has been completed.
Sponsor:
Collaborators:
The Danish Obesity Research Centre
Nordic Centre of Excellence
Arla Foods
Information provided by:
Aarhus University Hospital
ClinicalTrials.gov Identifier:
NCT00809874
First received: December 16, 2008
Last updated: November 9, 2009
Last verified: November 2009
  Purpose

The purpose of this study is to determine the effects of dietary protein on blood lipids and gut hormones after a fat-rich meal.

Hypothesis: Certain dietary proteins reduce the amount of fat circulating in the blood stream following a fat rich meal. The effect is dependant of both the quality and the quantity of protein ingested.


Condition Intervention
Postprandial Lipaemia Postprandial Incretins Postprandial Inflammation Dietary Supplement: Casein Dietary Supplement: Whey Isolate Dietary Supplement: Whey Hydrolysate Dietary Supplement: Alphalact-Albumin

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Prevention
Official Title: Effects of Dietary Proteins on Postprandial Lipaemia and Incretin Responses in Obese Subjects

Resource links provided by NLM:


Further study details as provided by Aarhus University Hospital:

Primary Outcome Measures:
  • Triglyceride [ Time Frame: 0h- 1h- 2h- 4h- 6h- 7h- 8h postprandial ]

Secondary Outcome Measures:
  • Incretins [ Time Frame: 0h -1h -2h -4h -6h -7h -8h Postprandial ]

Enrollment: 11
Study Start Date: February 2008
Study Completion Date: December 2008
Primary Completion Date: December 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Casein Dietary Supplement: Casein
Active Comparator: Whey Isolate Dietary Supplement: Whey Isolate
Active Comparator: Whey Hydrolysate Dietary Supplement: Whey Hydrolysate
Active Comparator: Alphalact-Albumin Dietary Supplement: Alphalact-Albumin

  Eligibility

Ages Eligible for Study:   40 Years to 75 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • BMI >30 kg/m2 & <45 kg/m2

Exclusion Criteria:

  • Diabetes
  • lipid lowering drugs
  • Liver-, Kidney- and/or Heart Disease
  • Serious Hypertension (160/110)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00809874

Locations
Denmark
Department of Clinical Nutrion
Aarhus, Denmark, 8000
Sponsors and Collaborators
Aarhus University Hospital
The Danish Obesity Research Centre
Nordic Centre of Excellence
Arla Foods
Investigators
Principal Investigator: K Hermansen, Professor, MD Department of Endocrinology and Metabolism, Aarhus University Hospital
  More Information

Responsible Party: Kjeld Hermansen, Professor, Chief Physician, MD, Dr.Med.Sci, Department of Endocrinology And Metabolism, Aarhus University Hospital
ClinicalTrials.gov Identifier: NCT00809874     History of Changes
Other Study ID Numbers: CERN-PPL-JHJ
Study First Received: December 16, 2008
Last Updated: November 9, 2009

Keywords provided by Aarhus University Hospital:
Postprandial Period
Postprandial Lipaemia
Incretins
Subclinical Inflammation
Obesity
Atherosclerosis
Triglyceride
Lipoproteins

Additional relevant MeSH terms:
Inflammation
Hyperlipidemias
Pathologic Processes
Dyslipidemias
Lipid Metabolism Disorders
Metabolic Diseases
Incretins
Caseins
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 21, 2017